[go: up one dir, main page]

MX2019008549A - Anticuerpos dirigidos a los huesos. - Google Patents

Anticuerpos dirigidos a los huesos.

Info

Publication number
MX2019008549A
MX2019008549A MX2019008549A MX2019008549A MX2019008549A MX 2019008549 A MX2019008549 A MX 2019008549A MX 2019008549 A MX2019008549 A MX 2019008549A MX 2019008549 A MX2019008549 A MX 2019008549A MX 2019008549 A MX2019008549 A MX 2019008549A
Authority
MX
Mexico
Prior art keywords
bone
antibodies
targeting antibodies
fragments
poly
Prior art date
Application number
MX2019008549A
Other languages
English (en)
Inventor
Qiu Huawei
Stefano James
Park Sunghae
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2019008549A publication Critical patent/MX2019008549A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos recombinantes y conjugados químicamente y fragmentos de los mismos modificados con uno o más péptidos poli-aspartato (poli-D) (p. ej., una secuencia D10) para mejorar la localización de los anticuerpos o fragmentos en hueso. También se describen métodos de fabricación y uso de estos anticuerpos y fragmentos.
MX2019008549A 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos. MX2019008549A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Publications (1)

Publication Number Publication Date
MX2019008549A true MX2019008549A (es) 2019-09-11

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.
MX2022008073A MX2022008073A (es) 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008073A MX2022008073A (es) 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos.

Country Status (17)

Country Link
US (3) US10844115B2 (es)
EP (1) EP3571226A2 (es)
JP (3) JP7227138B2 (es)
KR (3) KR102755284B1 (es)
CN (2) CN118121696A (es)
AR (1) AR110755A1 (es)
AU (1) AU2018210270A1 (es)
BR (1) BR112019013986A2 (es)
CA (1) CA3050884A1 (es)
IL (2) IL268114B2 (es)
MX (2) MX2019008549A (es)
MY (2) MY194819A (es)
SG (1) SG11201906663VA (es)
TW (3) TWI832600B (es)
UY (1) UY37576A (es)
WO (1) WO2018136698A2 (es)
ZA (1) ZA201907673B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027329A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
WO2019232280A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US20210155708A1 (en) * 2018-07-10 2021-05-27 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
WO2020104390A2 (en) * 2018-11-19 2020-05-28 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
EP4334347A1 (en) 2021-05-07 2024-03-13 Baylor College of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
JP2024526920A (ja) * 2021-07-20 2024-07-19 ウィリアム マーシュ ライス ユニバーシティ 骨標的療法のための操作された組成物
EP4426431A1 (en) * 2021-11-01 2024-09-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
EP4673179A1 (en) 2023-02-27 2026-01-07 William Marsh Rice University Bone-directed therapeutics for the treatment of cancer
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
EP1585771A4 (en) * 2002-12-31 2006-11-29 Altus Pharmaceuticals Inc COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS
EP1620128A1 (en) 2003-04-30 2006-02-01 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
AU2006213875B2 (en) 2005-02-08 2010-08-19 Genzyme Corporation Antibodies to TGFBETA
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7494651B2 (en) * 2005-12-23 2009-02-24 Eli Lilly And Company TGF-β binding antibodies
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
JP5774851B2 (ja) 2008-01-03 2015-09-09 ザ スクリプス リサーチ インスティテュート モジュラー認識ドメインを介してターゲティングする抗体
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
WO2010124276A2 (en) 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
DK2714735T3 (da) 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
CA2838952C (en) 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
CA2874918A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014062978A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
SG10201701985YA (en) * 2013-03-20 2017-04-27 Genzyme Corp Methods for treating osteogenesis imperfecta
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG11201604956SA (en) 2013-12-17 2016-07-28 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015140150A1 (en) * 2014-03-17 2015-09-24 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
RS60753B1 (sr) 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
ES3028883T3 (en) * 2015-08-31 2025-06-20 Nat Res Council Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
WO2018027329A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. TGF-β ANTAGONIST CONJUGATES
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso

Also Published As

Publication number Publication date
CN118121696A (zh) 2024-06-04
IL268114A (en) 2019-09-26
US20180208650A1 (en) 2018-07-26
JP7227138B2 (ja) 2023-02-21
JP2025028981A (ja) 2025-03-05
UY37576A (es) 2018-10-31
KR20190105236A (ko) 2019-09-16
IL268114B1 (en) 2025-01-01
KR20250012197A (ko) 2025-01-23
TW202421659A (zh) 2024-06-01
US20250074975A1 (en) 2025-03-06
CA3050884A1 (en) 2018-07-26
RU2019126026A (ru) 2021-02-20
AU2018210270A1 (en) 2019-09-05
US10844115B2 (en) 2020-11-24
CN111032690B (zh) 2024-03-26
TW202330597A (zh) 2023-08-01
AR110755A1 (es) 2019-05-02
WO2018136698A3 (en) 2018-08-30
MX2022008073A (es) 2022-07-27
US12098194B2 (en) 2024-09-24
KR102755284B1 (ko) 2025-01-22
US20210163584A1 (en) 2021-06-03
TW201839013A (zh) 2018-11-01
MY207919A (en) 2025-03-27
JP7597836B2 (ja) 2024-12-10
ZA201907673B (en) 2021-05-26
JP2020505919A (ja) 2020-02-27
WO2018136698A2 (en) 2018-07-26
RU2019126026A3 (es) 2021-11-09
TWI788321B (zh) 2023-01-01
KR102613463B1 (ko) 2023-12-15
EP3571226A2 (en) 2019-11-27
CN111032690A (zh) 2020-04-17
JP2023058590A (ja) 2023-04-25
KR20230172039A (ko) 2023-12-21
SG11201906663VA (en) 2019-08-27
IL317592A (en) 2025-02-01
TWI832600B (zh) 2024-02-11
MY194819A (en) 2022-12-17
BR112019013986A2 (pt) 2020-03-03
IL268114B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
MX2019008549A (es) Anticuerpos dirigidos a los huesos.
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
IL281192A (en) Interleukin-2 polypeptide conjugates and uses thereof
ECSP18082207A (es) Neoantígenos y métodos de su uso
PE20220256A1 (es) Sistemas de casx artificiales
PH12020551716A1 (en) Anti-ror antibody constructs
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
ZA202103511B (en) Engineered robust high tm-phytase clade polypeptides and fragments thereof
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
MX2017008660A (es) Polipeptidos enlazados a il-17a.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
JOP20200329A1 (ar) بروتينات وشظايا سائدة مناعيا في التصلب المتعدد
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
IL270917A (en) Recombinant ROBO2 proteins, preparations, methods and their use
MX2024002130A (es) Metodos y composiciones para mejorar la expresion de proteinas recombinantes.
AR117128A1 (es) Polipéptidos del clado de fitasa con alta tm robustos modificados por ingeniería genética y fragmentos de los mismos